ARTHROPLASTY, REPLACEMENT Clinical Trial
— AJRROfficial title:
American Joint Replacement Registry
NCT number | NCT01909375 |
Other study ID # | 1120353 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | August 2011 |
Est. completion date | December 2025 |
The American Joint Replacement Registry is a not-for-profit 501(c)(3) organization for data collection and quality improvement initiatives for total hip and knee replacements. The AJRR is a collaborative effort supported by the American Academy of Orthopaedic Surgeons (AAOS), the American Association of Hip and Knee Surgeons (AAHKS), The Hip Society, The Knee Society, hospitals, health insurers, medical device manufacturers, and contributions from individual orthopaedic surgeons.
Status | Recruiting |
Enrollment | 500000 |
Est. completion date | December 2025 |
Est. primary completion date | December 2025 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - Any individual in the US undergoing total joint arthroplasty Exclusion Criteria: - None |
Country | Name | City | State |
---|---|---|---|
United States | Nathan Glusenkamp | Rosemont | Illinois |
Lead Sponsor | Collaborator |
---|---|
American Joint Replacement Registry |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Knee Injury and Osteoarthritis Outcome Score - Joint Replacement (KOOS, JR) | 12 months | ||
Primary | Health Related Quality of Life | Utilization of VR-12 and/or PROMIS-10 | 12 months | |
Secondary | Hip disability and Osteoarthritis Outcome Score - Joint Replacement (HOOS, JR) | 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02728661 -
Patient-Centered Weight Loss Program for Knee Replacement Patients
|
Phase 1/Phase 2 | |
Recruiting |
NCT04080401 -
Effectiveness of a Novel Gaming System on Post-operative Rehabilitation Outcomes After Total Knee Arthroplasty
|
N/A | |
Completed |
NCT02648958 -
Effect of Dexmedetomidine on Ischemia-Reperfusion Injury in Lower Extremity Operations
|
N/A | |
Completed |
NCT00846807 -
Pradaxa (Dabigatran Etexilate 220 mg/q.d. in the General Population After Hip or Knee Replacement Surgery
|
N/A | |
Completed |
NCT04372173 -
An Evaluation of Clotting Factor Activity Before and After Total Hip Arthroplasty
|
||
Completed |
NCT01184989 -
Treatment of Patients Undergoing Primary Unilateral Elective Total Knee or Hip Replacement With Dabigatran Etexilate
|
Phase 4 | |
Terminated |
NCT01153698 -
Pradaxa (Dabigatran Etexilate) VTE Prevention After Elective Total Hip or Knee Replacement Surgery
|
||
Active, not recruiting |
NCT00114036 -
Trial to Reduce Antimicrobial Prophylaxis Errors (TRAPE)
|
N/A | |
Completed |
NCT03407885 -
The Impact of Medicare Bundled Payments
|
N/A | |
Completed |
NCT01857349 -
Efficacy of Surgical Preparation Solutions in Knee Surgery
|
N/A | |
Completed |
NCT00847301 -
Pradaxa (Dabigatran Etexilate) 150 mg/q.d. in Patients With Moderate Renal Impairment After Hip or Knee Replacement Surgery
|
N/A | |
Recruiting |
NCT04697004 -
SMR Stemless Reverse vs SMR Reverse Shoulder System
|
N/A | |
Completed |
NCT03158623 -
Wound Additives in Primary Total Joint Athroplasty
|
Phase 3 |